Speaker Profile
Brian Leyland-jones

Brian Leyland-jones MD, BS, PhD

Oncology, Hematology Blood and Marrow Transplant
Sioux Falls, South Dakota, United States of America

Connect with the speaker?

Brian Leyland-Jones, MB BS, PhD, is Vice President of Molecular and Experimental Medicine at Avera Cancer Institute and Professor of the Department of Internal Medicine at the University of South Dakota, Sanford School of Medicine in Sioux Falls, South Dakota. He is also a Consulting Professor in the Division of Oncology at Stanford University School of Medicine in Stanford, California.Prof. Leyland-Jones holds biochemistry, medical, and doctoral degrees from the University of London. Following residency training at Hammersmith, Brompton, St. Bartholomew’s and London hospitals, he completed a clinical pharmacology fellowship at Cornell University and a medical oncology fellowship at Memorial Sloan-Kettering Cancer Center. He then joined the academic staff at Memorial Sloan-Kettering Cancer Center and New York Hospitals with a special research interest in Early Phase clinical, clinical pharmacological and biomarker evaluation of many anticancer compounds, including the platinums and anthracycline analogs in use today.

In 1983, he moved to the National Cancer Institute (NCI) to head the Developmental Chemotherapy section. During his time with the NCI, he was responsible for the overall development of approximately 70 anti-cancer compounds in various stages of transition from in-vitro screening to Phase III clinical trials, including overseeing the early development of paclitaxel in Phase 1 and 2 trials. From 1990 to 2000, he served as founding chair of Oncology and director of the McGill University Comprehensive Cancer Centre. He recruited and built a broad multifaceted cancer centre, including a robust cross-hospital clinical trials enterprise, with deep clinical pharmacologic and biomarker support. Prof Leyland-Jones continued as the Minda de Gunzberg Chair in Oncology and professor of medicine at McGill University in Montreal, Canada for 7 additional years, focusing on the development and biomarker strategies of several of the new targeted oncologic agents.
EVENTS & ACTIVITIES (Speaking, Spoken, and Authored)